Defying recent prophecies of doom for proteomics service companies, both Oxford GlycoSciences and MDS Proteomics announced new research partnerships last week that will provide them with fresh revenues and bring OGS closer to its stated goal of leading its proteomics division to profitability this year.
While OGS reached a new agreement with its longstanding partner Pfizer, MDSP signed a five-year contract with biotechnology company Cephalon.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
